Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

17.01.2018 | review

Role of complement in the pathogenesis of thrombotic microangiopathies

verfasst von: Eszter Trojnár, Ágnes Szilágyi, Bálint Mikes, Dorottya Csuka, György Sinkovits, Prof. Zoltán Prohászka

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Summary

Thrombotic microangiopathies (TMAs) are rare but life-threatening disorders characterized by microvascular hemolytic anemia and acute thrombocytopenia with or without organ damage. The term TMA covers various subgroups of diseases, the pathogenesis of which is briefly summarized in this review. As highlighted here, complement activation may represent an important amalgamating process in all of these conditions, since it is able to link together activation and damage of multiple involved cell types, such as endothelial cells, platelets, and neutrophils.
Vorheriger Artikel Thrombotic thrombocytopenic purpura
Nächster Artikel Hemoglobinopathies—genetically diverse, clinically complex, and globally relevant
Literatur
1.
Warwicker P, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836–44.CrossRefPubMed
2.
Szarvas N, et al. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Mol Immunol. 2016;71:10–22.CrossRefPubMed
3.
Caprioli J, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–79.CrossRefPubMedPubMedCentral
4.
Westra D, et al. Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H‑related 5 gene. J Hum Genet. 2012;57(7):459–64.CrossRefPubMedPubMedCentral
5.
Jozsi M, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111(3):1512–4.CrossRefPubMed
6.
7.
Thurman JM, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4(12):1920–4.CrossRefPubMedPubMedCentral
8.
Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011;117(20):5503–13.CrossRefPubMed
9.
Westra D, et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol. 2017;32(2):297–309.CrossRefPubMed
10.
Orth D, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol. 2009;182(10):6394–400.CrossRefPubMed
11.
Arvidsson I, et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol. 2015;194(5):2309–18.CrossRefPubMed
12.
Morigi M, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187(1):172–80.CrossRefPubMed
13.
14.
Bettoni S, et al. Interaction between multimeric von Willebrand factor and complement: a fresh look to the pathophysiology of microvascular thrombosis. J Immunol. 2017;199(3):1021–40.CrossRefPubMed
15.
Reti M, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(5):791–8.CrossRefPubMed
16.
17.
Mikes B, et al. Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura. Thromb Res. 2014;133(4):616–21.CrossRefPubMed
18.
Ruiz-Torres MP, et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost. 2005;93(3):443–52.PubMedCrossRef
19.
Jodele S, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122(12):2003–7.CrossRefPubMedPubMedCentral
20.
Gloude NJ, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood. 2017;130(10):1259–66.CrossRefPubMedPubMedCentral
21.
Yuen J, et al. NETosing neutrophils activate complement both on their own NETs and bacteria via alternative and non-alternative pathways. Front Immunol. 2016;7:137.CrossRefPubMedPubMedCentral
22.
Farkas P, et al. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology. 2017;222(2):119–27.CrossRefPubMed
23.
Cofiell R, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125(21):3253–62.CrossRefPubMedPubMedCentral
24.
Azukaitis K, et al. The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase epsilon. J Am Soc Nephrol. 2017;28(10):3066–75.CrossRefPubMedPubMedCentral
25.
26.
Leffler J, et al. Decreased neutrophil extracellular trap degradation in Shiga toxin-associated haemolytic uraemic syndrome. J Innate Immun. 2017;9(1):12–21.CrossRefPubMed
27.
Lukasz A, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS). Thromb Haemost. 2014;111(2):365–72.CrossRefPubMed
28.
Huang DT, et al. T‑antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia. Pediatr Infect Dis J. 2006;25(7):608–10.CrossRefPubMed
29.
Szilagyi A, et al. The use of a rapid fluorogenic neuraminidase assay to differentiate acute streptococcus pneumoniae-associated hemolytic uremic syndrome (HUS) from other forms of HUS. Clin Chem Lab Med. 2015;53(4):e117–e9.CrossRefPubMed
30.
Mikes B, et al. Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura. Thromb Haemost. 2016;115(5):1034–43.CrossRefPubMed
31.
Bettoni G, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(8):1556–65.CrossRefPubMed
Metadaten
Titel
Role of complement in the pathogenesis of thrombotic microangiopathies
verfasst von
Eszter Trojnár
Ágnes Szilágyi
Bálint Mikes
Dorottya Csuka
György Sinkovits
Prof. Zoltán Prohászka
Publikationsdatum
17.01.2018
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0380-y

Weitere Artikel der Ausgabe 3/2018

Post SABCS local therapy and radiology

  • Open Access
  • short review

Cure in metastatic breast cancer

  • Open Access
  • short review

My burning issues in the management of liver metastases of advanced colorectal cancer

  • comment

Still making progress

  • editorial

Current concepts and future directions in neoadjuvant chemotherapy of breast cancer

  • Open Access
  • review

Hemoglobinopathies—genetically diverse, clinically complex, and globally relevant

  • short review